In part, this may be due to the fact that we had to use immunodeficient mice as hosts for human tumor cells because TGF-β pathway antagonists have been shown to de-repress anti-tumor immunity in mouse models of mammary cancer [48,49,52-54]. This evidence concerns the gene TGFB1 and neoplasm.